SubHero Banner

Xultophy® 100/3.6 (insulin degludec/liraglutide) – New drug approval

November 21, 2016 – Novo Nordisk announced the FDA approval of Xultophy 100/3.6 (insulin degludec/liraglutide) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin (< 50 units daily) or liraglutide (≤ 1.8 mg daily).

Download PDF